Investor Presentaiton

Targeted Protein Degradation offers the promise of novel targets and clinical differentiation for existing targets Expanded universe of targets (e.g., scaffolding proteins, transcription factors) Drugged: Target with approved drugs (3%) "Dark Druggable: No approved drugs, but bind small molecules with high potency (8%) Small molecule enzyme inhibitor 659 Genome": (3%) 1,607 No known (8%) 6,007 disease (30%) association (30%) Human protein - Coding genes ~20,000 Disease- relevant: No known potent binders, but implicated in disease (61%) Scaffold 12,139 (61%) Opportunity for TPD Scaffold protein Transcription factor Ill Bristol Myers Squibb™ Not for Product Promotional Use 30

View entire presentation